Showing 1 posts of 1 posts found.
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
Artificial hearts: a century of innovation